Oruka Therapeutics, Inc. ORKA Total Revenue
Discontinued — last reported Q2 '24
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed August 1, 2024.
- Filed
- Aug 1, 2024
- Fiscal quarter
- Q2 FY2024
- Calendar quarter
- Q2 2024
- Accession
- 0000950170-24-089246
The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. The Company has historically funded its operations through issuances of common and preferred stock.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Oruka Therapeutics, Inc.'s total revenue?
- Oruka Therapeutics, Inc. (ORKA) reported total revenue of $0 in Q2 2024.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Oruka Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
